Isolated Positive Toxoplasma Gondii PCR in Blood
Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Jun 27, 2025
Trial Information
Current as of September 08, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study is looking at a blood test called PCR that can detect a parasite called Toxoplasma gondii, which can cause a serious infection called toxoplasmosis, especially in people with weakened immune systems. Sometimes, this test shows the parasite’s DNA in the blood even when a person has no symptoms or signs of illness. The researchers want to understand whether a positive test means the person will develop toxoplasmosis disease or just has the infection without getting sick. By reviewing past cases from multiple hospitals, they hope to find clues from medical exams, blood tests, or scans that can help doctors predict what will happen after a positive test.
People who might join this study are those who had a positive Toxoplasma PCR blood test during the study period but did not have any symptoms of toxoplasmosis since their last negative test, and who have not had a positive test in the past six weeks. The study excludes people with certain types of toxoplasmosis, like eye infections or those related to HIV, or those with a recent acute infection. Participants won’t have new tests or treatments as part of the study since it looks back at existing medical records. This research aims to help doctors better understand and manage patients who test positive for this parasite but don’t yet feel sick.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • T. gondii positive-PCR in blood during the study period: no symptoms of toxoplasmosis since the last systematic PCR negative in blood and no history of T. gondii positive-PCR in any biological matrix for 6 weeks.
- Exclusion Criteria:
- • pre-analytical or analytical error leading to a false-positive result
- • unknown toxoplasmosis immune status or non-immune subject
- • serology in favor of acute toxoplasmosis
- • congenital toxoplasmosis, ocular toxoplasmosis, toxoplasmosis in the context of HIV/AIDS
- • patient opposition
About University Hospital, Clermont Ferrand
The University Hospital of Clermont-Ferrand is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes collaboration among healthcare professionals, researchers, and academic partners. With a strong commitment to improving patient outcomes, the institution actively engages in a wide array of clinical studies, ranging from early-phase trials to large-scale interventions, aimed at addressing critical health challenges and enhancing treatment modalities. Its state-of-the-art facilities and expertise make it a pivotal contributor to clinical research in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clermont Ferrand, , France
Patients applied
Trial Officials
Céline NOURRISSON
Principal Investigator
CHU de Clermont-Ferrand
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported